As IMA data lacks diagnostic information, patients diagnosed with T2D are algorithmically identified based on the proxies taking T2D medication (metformin, sulfonylurea, insulin) or having a pre-diabetes pass (registration in this care trajectory allows the reimbursement of a consult with a dietician, podiatrist and diabetes educator) in year [x-1] [48, 49, 66]. This evidence concerns the gene INS and type 2 diabetes mellitus.